Sales of Novo Nordisk's weight-loss drug Wegovy surged by 86% last year, leading to higher-than-expected revenues. Despite concerns over potential Trump tariffs, the company remains confident in its ability to meet demands. Novo is now Europe’s most valuable company amidst soaring demand for anti-obesity treatments.
Novo Nordisk Confident Despite Trump Tariff Risk, Sales Surge
✨ Enjoying this article? ✨
📱 Get more with the NewsNuggs iOS App →